Terms: = Skin cancer AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254 AND Treatment
11 results:
1. Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma.
Pennington TE; Zhao CY; Colebatch AJ; Fernandez-Peñas P; Guitera P; Burke H; Scolyer RA; Menzies AM; Carlino MS; Lo S; Long GV; Saw RP
Australas J Dermatol; 2022 May; 63(2):e133-e137. PubMed ID: 35188271
[TBL] [Abstract] [Full Text] [Related]
2. Complete Bone Marrow Necrosis with Charcot-Leyden Crystals Caused by Myeloid Neoplasm with Mutated npm1 and TET2.
Saito K; Sato T; Notohara K; Nannya Y; Ogawa S; Ueda Y
Intern Med; 2022 Nov; 61(21):3265-3269. PubMed ID: 35185048
[TBL] [Abstract] [Full Text] [Related]
3. Dactinomycin in acute myeloid leukemia with npm1 mutations.
Beziat G; Tavitian S; Bertoli S; Huguet F; Largeaud L; Luquet I; Vergez F; Rieu JB; Bories P; Delabesse E; Récher C
Eur J Haematol; 2020 Sep; 105(3):302-307. PubMed ID: 32452083
[TBL] [Abstract] [Full Text] [Related]
4. Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma.
Melchers RC; Willemze R; van de Loo M; van Doorn R; Jansen PM; Cleven AHG; Solleveld N; Bekkenk MW; van Kester MS; Diercks GFH; Vermeer MH; Quint KD
Am J Surg Pathol; 2020 Jun; 44(6):776-781. PubMed ID: 32412717
[TBL] [Abstract] [Full Text] [Related]
5. New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
Diamantopoulos PT; Lakiotaki E; Kyriakakis G; Gogas H
Melanoma Res; 2020 Apr; 30(2):206-208. PubMed ID: 31157737
[TBL] [Abstract] [Full Text] [Related]
6. Proteomic Analysis and Functional Studies of Baicalin on Proteins Associated with skin cancer.
Li D; Lin B; Yusuf N; Burns EM; Yu X; Luo D; Min W
Am J Chin Med; 2017; 45(3):599-614. PubMed ID: 28385077
[TBL] [Abstract] [Full Text] [Related]
7. Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.
Veija T; Koljonen V; Bohling T; Kero M; Knuutila S; Sarhadi VK
BMC Cancer; 2017 Mar; 17(1):236. PubMed ID: 28359267
[TBL] [Abstract] [Full Text] [Related]
8. A novel recurrent npm1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.
Velusamy T; Kiel MJ; Sahasrabuddhe AA; Rolland D; Dixon CA; Bailey NG; Betz BL; Brown NA; Hristov AC; Wilcox RA; Miranda RN; Medeiros LJ; Jeon YK; Inamdar KV; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Dec; 124(25):3768-71. PubMed ID: 25349176
[TBL] [Abstract] [Full Text] [Related]
9. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM
Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794
[TBL] [Abstract] [Full Text] [Related]
10. Chronic exposure to 12-O-tetradecanoylphorbol-13-acetate represses sod2 induction in vivo: the negative role of p50.
Dhar SK; Xu Y; Noel T; St Clair DK
Carcinogenesis; 2007 Dec; 28(12):2605-13. PubMed ID: 17652337
[TBL] [Abstract] [Full Text] [Related]
11. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese Patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid.
Chou WC; Su IJ; Tien HF; Liang DC; Wang CH; Chang YC; Cheng AL
Cancer; 1996 Oct; 78(8):1805-12. PubMed ID: 8859196
[TBL] [Abstract] [Full Text] [Related]
